Medicare Part D spending · FDA facts · help paying
Ocrevus (ocrelizumab): what Medicare Part D spends and the dated federal facts we hold
CMS's Medicare Part D spending dataset reports gross spending on Ocrevus of $195.07 million in 2024, across 5,163 claims and 3,085 beneficiaries. 1 assistance program lists ocrelizumab, each with its income ceiling and when we read it. 1 non-manufacturing label change is dated in the last 12 months in the FDA's file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Ocrevus of $195.07 million in 2024, across 5,163 claims and 3,085 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $195.07 million | 5,163 | 3,085 | $37,782 |
| 2023 | $157.05 million | 4,169 | 2,492 | $37,671 |
| 2022 | $123.05 million | 3,433 | 2,079 | $35,842 |
| 2021 | $96.64 million | 2,858 | 1,758 | $33,813 |
| 2020 | $81.04 million | 2,524 | 1,577 | $32,109 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicare Part B payment limit
CMS publishes a quarterly payment limit for the HCPCS code that its NDC crosswalk links to Ocrevus. It is a ceiling for providers who bill Medicare Part B, not a price a patient pays, and a code's presence says nothing about whether Medicare covers a product.
| HCPCS code | Quarter | Payment limit | Per dosage descriptor | Effective | Read |
|---|---|---|---|---|---|
| J2350 | 2026 Q4 | $60.69 | 1 MG | October 1, 2026 through December 31, 2026 | November 7, 2026 |
Source: CMS ASP pricing files (october-2026-medicare-part-b-payment-limit-files-final.zip and the matching NDC-HCPCS crosswalk). CMS ASP pricing files page.
Biosimilar status
- Ocrevus (ocrelizumab) is a reference product in the FDA Purple Book (BLA 761053, approved March 28, 2017). The Purple Book lists 0 biosimilars and 0 interchangeable products that name it as their reference product.
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 1 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| WY | 107 | $2,299,828 | All record types |
A state missing from the table means its figures were suppressed or not reported, not zero use. 41 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Medicaid spending
CMS's Medicaid spending dataset reports $407.25 million for Ocrevus in 2024. CMS's dataset states spending includes Federal and State reimbursement and dispensing fees and is not reduced by Medicaid rebates paid to the states. Spending is what Medicaid paid, not what a patient pays.
| Year | Spending | Claims |
|---|---|---|
| 2024 | $407.25 million | 14,446 |
| 2023 | $410.45 million | 15,163 |
| 2022 | $366.50 million | 14,031 |
| 2021 | $297.20 million | 11,969 |
| 2020 | $233.31 million | 9,638 |
Source: CMS Medicaid spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. A national drug-level aggregate; it says nothing about any state's coverage rules.
Federal formulary status
VA national formulary
The VA's national formulary files list the ingredient ocrelizumab, which covers every maker's product with that ingredient, not only Ocrevus. Each row is a VA national drug file entry and its status.
| VA entry | Status | Active NDCs |
|---|---|---|
| OCRELIZUMAB INJ,SOLN | Non-formulary | 1 |
Source: VA Pharmacy Benefits Management national formulary (va-formulary-2026-09), read November 7, 2026. VA formulary page.
Where help paying exists
Offers the program pages state
- Manufacturer savings card
The Ocrevus financial-support page states a Co-pay Program for commercially insured patients: as little as $0 per treatment, with co-pay assistance of up to $20,000 per calendar year, and administration assistance up to $1,500 per calendar year in the first year and up to $1,000 each calendar year after. Maximum benefits reset every January 1st.
Read November 7, 2026; quote matched against the saved page text.
Programs in our finder that list ocrelizumab. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Genentech/Roche Access Solutions manufacturer
Household income under $150,000 for 1 to 4 people if uninsured or your plan does not cover the medicine (Genentech Patient Foundation)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Ocrevus dated since November 11, 2025, leaving out manufacturing (CMC) changes. 1 change in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| May 8, 2026 | Efficacy | BLA761053 | 38 | Label (PDF) posted May 18, 2026FDA letter posted May 11, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Questions
Does Medicare have a negotiated price for Ocrevus?
The CMS negotiated-price file we read does not list Ocrevus, so this page shows no negotiated price. A drug appears in that file only when CMS selects it for negotiation, and not being listed says nothing about what it costs a patient.
Is there help paying for Ocrevus?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
How much does Medicare Part D spend on Ocrevus?
CMS's Medicare Part D spending dataset reports gross spending on Ocrevus of $195.07 million in 2024, across 5,163 claims and 3,085 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns the generic-entry upper bound, label history, recalls, trials, assistance and Part D spending, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/ocrevus.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. This drug is not in the CMS negotiated-price file, so no price source is used. Program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS Medicaid spending by drug; TRICARE and VA formulary files; CMS ASP pricing files; FDA Purple Book; FDA Drugs@FDA and Orange Book data files. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.